Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock
January 15, 2019 22:04 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
January 14, 2019 16:35 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS™
January 07, 2019 09:50 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 02, 2019 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting
December 06, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting
November 30, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA)
November 20, 2018 07:00 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
November 16, 2018 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Reports Third Quarter 2018 Financial Results
November 08, 2018 16:01 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting
November 02, 2018 07:30 ET
|
Stemline Therapeutics, Inc.
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...